SCHEMBL7264993

SCHEMBL7264993

C=CCc1cc(Cl)cc(C(=O)OC)c1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 2/20 0.42
THRB P10828 1/20 0.42
PTGDR Q13258 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
KDM4E B2RXH2 5/20 0.40
SERPINH1 P50454 1/20 0.39
ABL1 P00519 1/20 0.39
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
PDK2 Q15119 1/20 0.38
GABRA1 P14867 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
GABRA2 P47869 1/20 0.37
GABRB2 P47870 1/20 0.37
MEN1 O00255 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7265468 0.87 ALDH1A1 (0.45) ALDH1A1HPGDHSD17B10MAPTKDM4E
SCHEMBL14372980 0.84 GAA (0.41) ALDH1A1HPGDHSD17B10MAPTKDM4E
SCHEMBL12283876 0.84 KDM4E (0.46) ALDH1A1HPGDHSD17B10MAPTKDM4E
SCHEMBL30810266 0.83 HPGD (0.50) ALDH1A1HPGDHSD17B10MAPTKDM4E
SCHEMBL3935495 0.82 KDM4E (0.39) ALDH1A1HPGDMAPTKDM4EPDK2
SCHEMBL642229 0.82 KDM4E (0.43) ALDH1A1HPGDMAPTKDM4EGABRA1
SCHEMBL29116913 0.82 KDM4E (0.40) ALDH1A1HPGDMAPTKDM4EGABRA1
SCHEMBL7388417 0.81 KDM4E (0.57) ALDH1A1HPGDMAPTKDM4EMEN1
SCHEMBL14466455 0.81 ABL1 (0.50) ALDH1A1HPGDMAPTTHRBPTGDR
SCHEMBL12035850 0.79 ALDH1A1 (0.44) ALDH1A1HPGDHSD17B10MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-04-20 US disclosed
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-04-20 US disclosed
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2017-04-20 US disclosed
EP-3109239-A1 AMINOPYRAZOLONE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2016-12-28 EP disclosed
WO-2015125785-A1 PYRAZOLONE DERIVATIVE HAVING MULTIPLE SUBSTITUENTS 第一三共株式会社 2015-08-27 WO disclosed
WO-2015125786-A1 AMINOPYRAZOLONE DERIVATIVE 第一三共株式会社 2015-08-27 WO disclosed
US-5175173-A Reduced side effects SUN JUNG HUI (US) 1992-12-29 US disclosed
US-5126364-A Antiemetics, antipsychotics ERBAMONT, INC. (US) 1992-06-30 US disclosed
EP-0234872-B1 CARBOXAMIDES USEFUL AS ANTIEMETIC OR ANTIPSYCHOTIC AGENTS Erbamont Inc. (US) 1991-11-27 EP disclosed
EP-0147044-B1 BENZOFURANCARBOXAMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM ADRIA LABORATORIES INC. (US) 1990-04-25 EP disclosed
US-4888353-A Carboxamides useful as antiemetic or antipsychotic agents ERBAMONT, INC. (US) 1989-12-19 US disclosed
EP-0234872-A1 Carboxamides useful as antiemetic or antipsychotic agents Erbamont Inc. (US) 1987-09-02 EP disclosed
EP-0147044-A2 Benzofurancarboxamides, process for their preparation and pharmaceutical preparations containing them ADRIA LABORATORIES INC. (US) 1985-07-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170107207-A1 AMINOPYRAZOLONE DERIVATIVE ATAD5, ATP1A1, TIPRL ALDH1A1 2821/4885HPGD 4083/4885HSD17B10 3342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.